Leishmania enriettii: immune induction of macrophage activation in an experimental model of immunoprophylaxis in the mouse

Preclinical Toxicology of Vaccines1

Immunity to targeted infectious diseases may be conferred or enhanced by vaccines, which are manufactured from recombinant forms as well as inactivated or attenuated organisms. These vaccines have to meet requirements for safety, quality, and efficacy. In addition to antigenic components, various adjuvants may be included in vaccines to evoke an effective immune response. To ensure the safety of new vaccines, preclinical toxicology studies are conducted prior to the initiation of, and concurrently with, clinical studies. There are five different types of preclinical toxicology study in the evaluation of vaccine safety: single and/or repeat dose, reproductive and developmental, mutagenicity, carcinogenicity, and safety pharmacology. If any adverse effects are observed in the course of these studies, they should be fully evaluated and a final safety decision made accordingly. Successful preclinical toxicology studies depend on multiple factors including using the appropriate study designs, using the right animal model, and evoking an effective immune response. Additional in vivo and in vitro assays that establish the identity, purity, safety, and potency of the vaccine play a significant role in assessing critical characteristics of vaccine safety.

Leishmaniasis: current status of vaccine development

Leishmaniae are obligatory intracellular protozoa in mononuclear phagocytes. They cause a spectrum of diseases, ranging in severity from spontaneously healing skin lesions to fatal visceral disease. Worldwide, there are 2 million new cases each year and 1/10 of the world's population is at risk of infection. To date, there are no vaccines against leishmaniasis and control measures rely on chemotherapy to alleviate disease and on vector control to reduce transmission. However, a major vaccine development program aimed initially at cutaneous leishmaniasis is under way. Studies in animal models and humans are evaluating the potential of genetically modified live attenuated vaccines, as well as a variety of recombinant antigens or the DNA encoding them. The program also focuses on new adjuvants, including cytokines, and delivery systems to target the T helper type 1 immune responses required for the elimination of this intracellular organism. The availability, in the near future, of the DNA sequences of the human and Leishmania genomes will extend the vaccine program. New vaccine candidates such as parasite virulence factors will be identified. Host susceptibility genes will be mapped to allow the vaccine to be targeted to the population most in need of protection.

New isolation of Leishmania enriettii Muniz and Medina, 1948 in Paranástate, Brazil, 50 years after the first description, and isoenzymatic polymorphism of the L. enriettii taxon

Three cases of cutaneous leishmaniasis in guinea-pigs from a rural area near Curitiba (Paraná State, Brazil) are reported. The three parasite isolates were characterized by isoenzyme electrophoresis as Leishmania enriettii, of which two distinct zymodemes were observed.

Macrophage activation in vitro by lymphocytes from Leishmania major infected healer and non-healer mice

Peritoneal macrophages from CBA/T6 (healer) and BALB/c (non-healer) mice were infected with Leishmania major (LV39) in vitro. The microorganism replicated at the same rate in macrophages from either strain. Exposure of infected cells to lymph node cells (LNC) from infected syngeneic animals led to intracellular killing of the parasite by macrophages from both strains, provided LPS was present in the incubation medium. In vitro-propagated L.major-specific T-cell blasts activated macrophages from either strain in the absence of LPS. On a per cell basis, lymphoid cells from BALB/c mice were less efficient, however, than cells from CBA/T6 mice. Lysis of parasitized macrophages was also more marked in CBA/T6 than in BALB/c cell mixtures. LNC exposed to parasite antigen or to infected macrophages secreted macrophage-activating factor (MAF); incubation with antigen also induced lymphocyte proliferation. MAF production and LNC proliferation decreased with progression of the infection of BALB/c mice, but always remained significant. The reduction in relative T-cell numbers in the lymph nodes of infected animals was moderate; the absolute number of T-cells increased markedly in the lymphoid organs of both strains, however. These results suggest that failure to heal may coexist together with active cell-mediated immune response in non-healer mice.

Vaccination of mice against Leishmania mexicana amazonensis with microsomal fraction associated with BCG

Attempts to develop a satisfactory vaccine against New World cutaneous leishmaniasis have been made with varying success. We found that in mice, pretreated subcutaneously with 2 X 10(6) BCG organisms 2 weeks prior to immunization at the same site with as low as 10 micrograms of a microsomal preparation (Pol-F) of Leishmania mexicana amazonensis, a profound alteration was observed in the course of infection produced by inoculation of virulent amastigotes of the same strain. The BCG-Pol-F vaccine preparation was consistently shown to have a protective capacity associated with larger classical cellular immune response (skin test) and higher specific antibody titres in response to leishmanial challenge dose (1 X 10(6) amastigotes/mouse).

T-cell clones in immunoparasitology

Cell-mediated immunity (CMI) is important in many parasitic infections. Stimulation by parasite-specific antigens can induce clonal expansion of parasite-specific T-cells which may act by direct cytotoxic action or by indirect effects on other cells such as natural killer cells or antibody-producing B-cells (Box 1). In many cases however, the precise effector functions and the identity of antigens that elicit protective responses in parasitic infections are poorly defined. Analysis of proliferative and cytotoxic activities of subcloned cultures of T-cells stimulated with parasite antigens can provide some clues about the importance of CMI, but, as this review shows, much more precise information can be obtained by analysis of the response of cloned T-cell cultures.

Variable expression of the murine natural resistance gene Lsh in different macrophage populations infected in vitro with Leishmania donovani

Various macrophage populations isolated from mice (including congenic C57BL/10ScSn and B10.LLshr) bearing resistant or susceptible alleles for the natural resistance gene (Lsh) were infected with Leishmania donovani amastigotes in vitro and examined (a) for their ability to support growth of the amastigote population over 7 days of culture in vitro, and (b) for their ability to express Lsh gene controlled resistance and susceptibility in vitro. Resident macrophages from liver (Kupffer cells), spleen and lung, as well as 7-day bone marrow-derived macrophages and bone marrow macrophages obtained after 6 weeks of continuous culture in vitro, all supported growth of the amastigote population. Of these, significant differences in amastigote numbers in macrophages from Lshs and Lshr mice were observed after 48 h of infection in vitro for liver, lung and 7-day bone marrow macrophage populations only. Resident peritoneal macrophages grown in adherent or suspension cultures neither supported growth of the amastigote population nor showed any evidence of Lsh gene expression in vitro. Hence, multiplication of the parasite appeared to be a necessary but not sufficient condition for observation of Lsh gene activity against L. donovani in vitro. Use of tritiated thymidine incorporation and autoradiography to label dividing amastigotes showed equivalent multiplication of the parasite in liver macrophages from Lshs and Lshr mice between 24 h and 48 h after infection in vitro, with a dramatic difference observed thereafter. This was consistent with earlier observations of a 2-3 day delay in expression of Lsh gene controlled resistance in vivo. Comparison with studies using Salmonella typhimurium and Mycobacterium bovis suggests that the gene may be restricted in its action to a particular point in the parasite cell cycle, perhaps at the level of regulating DNA replication.

Cell-mediated immunity in experimental cutaneous leishmaniasis

Forms of cutaneous leishmaniasis are caused by Leishmania major, L. tropica, L. mexicana, L. amazonensis and L. panamensis. Like all leishmanial species, these are obligate intracellular parasites of the mononuclear phagocyte system, with a restricted range of vertebrate hosts including humans, dogs, rodents and arboreal animals. The disease evolves chronically, usually with slow healing, but can sometimes become nonhealing, diffuse disseminating or relapsing. The parasite exists within the macrophages of the vertebrate host in the amastigote form. These transform into extracellular flagellated promastigotes in the gut of the sandfly vectors. The promastigotes can then be injected into new vertebrate hosts as the insects feed. Promastigotes, and to a lesser extent amastigotes, can now be grown in tissue culture. This, together with the use of inbred mouse strains that are susceptible to most of the Leishmania species which are pathogenic for man, has facilitated great advances in our understanding of the immunological control of leishmaniasis. However, as Eddy Liew points out, there are still many unanswered questions.

Intracellular parasite killing induced by electron carriers. II. Correlation between parasite killing and the induction of oxidative events in macrophages

Mouse peritoneal macrophages infected with Leishmania parasites were exposed in vitro to the electron carriers methylene blue (MB), toluidine blue 0 (TB), phenazine methosulfate (PMS) and crystal violet (CV). This led to parasite destruction without harm to the macrophages. The kinetics of intracellular killing depended on both the drug concentration and the duration of exposure; over 80% of the microorganisms were inactivated within 2.5 min of incubation of the parasitized cells with 10(-4) M MB. On a molar basis, the drugs were considerably more active against intracellular compared to free parasites, suggesting that the macrophages themselves play a role in the observed anti-parasite toxicity. Intracellular killing by macrophages exposed to MB, TB and PMS correlated with the stimulation of oxygen uptake and hexose monophosphate shunt activity in the cells. Cytochrome c markedly inhibited MB-induced intracellular parasite destruction as well as completely blocking parasite killing in macrophages activated by lymphokines, pointing to O-2, H2O2 or products derived therefrom as possible mediators of macrophage toxic activity in both instances. Cytochrome c did not protect free parasites from the direct toxicity of the drug, however. Lipopolysaccharide promoted parasite destruction by lymphokine-activated macrophages, but failed to do so for electron carrier-stimulated cells. These observations suggest that intracellular killing induced by electron carriers results from a direct interaction of the drugs with cellular redox systems, leading to the generation of oxygen metabolites toxic for the parasites.

Induction by specific T lymphocytes of intracellular destruction of Leishmania major in infected murine macrophages

The following cell populations derived from lymph nodes of mice primed in vivo with living Leishmania major promastigotes were tested for their capacity to induce parasiticidal activity in L. major-infected macrophages: a L. major-primed lymph node cells, draining lymph node cells from mice primed by a subcutaneous injection of living L. major in Freund's Complete Adjuvant; b L. major-specific T blasts, i.e. blast T cells resulting from in vitro challenge of primed lymph node cells with L. major, c propagated L. major specific T blasts, i.e. blast T cells after propagation in vitro in antigen-free medium containing interleukin-2. Results indicate that cocultivation of these L. major specific lymphocyte populations with infected peritoneal exudate macrophages induced progressive destruction of intracellular L. major. This effect was antigen specific since similar populations obtained from mice primed either with ovalbumin or bovine serum albumin did not induce significant parasite killing. The various lymphocyte populations examined did not express cytolytic activity for syngeneic macrophages infected with L. major when tested in a short-term 51Cr release assay. These negative results could not be attributed to an inability of infected macrophages to be lysed by cytolytic lymphocytes since cytolytic T lymphocytes directed to H-2 alloantigens present on macrophages were perfectly capable of lysing these infected macrophages as revealed in a 4 h 51Cr release assay. Interestingly, infected macrophages from either BALB/c (H-2d), NZB (H-2d) or CBA (H-2k) mice were lysed by cytolytic T lymphocytes specific for their respective H-2 alloantigens as well as uninfected macrophages. These results suggest that H-2 expression on the surface of infected macrophages from either L. major susceptible or resistant mouse strains is sufficient to be detected by allogeneic cytolytic T lymphocytes.

Antileishmanial activities of macrophages from C3H/HeN and C3H/HeJ mice treated with Mycobacterium bovis strain BCG

C3H/HeN and C3H/HeJ mice were infected ip with viable BCG, a macrophage-activating agent, and their peritoneal exudate macrophages exposed to Leishmania tropica amastigotes. Macrophages from BCG-infected C3H/HeN mice had both leishmanicidal activities described for lymphokine activation of C3H/HeN macrophages in vitro: increased resistance to L. tropica infection, followed by intracellular killing of the parasite. Macrophages from BCG-infected C3H/HeN mice were also activated to kill tumor cells in vitro. In contrast, macrophages from BCG-treated C3H/HeJ mice were not resistant to L. tropica infection, did not kill intracellular amastigotes over 72 hr in culture, and were not cytotoxic to tumor cells.

Macrophage activation and effector mechanisms against microbes

The term activation is used to designate biochemical and functional changes that are induced in macrophages by a variety of stimuli, including interaction with microbial products, synthetic substances, immunoglobulins of different classes, and factors released by lymphocytes. The changes observed comprise an increased capacity to destroy intracellular microorganisms and non-microbial target cells as well as the stimulation of biochemical pathways leading to the release of enzymes and the generation of various toxic compounds. Activation may thus be viewed as a process aimed at recalling those metabolic functions that are necessary for killing, when phagocytosis has failed to evoke them. The increased microbicidal capacity of activated macrophages is linked to the production of oxygen intermediates, as illustrated by the study of macrophage toxicity for certain intracellular protozoan parasites. Scavengers of oxygen metabolites inhibit parasite killing in macrophages; on the contrary, agents that stimulate the production or utilization of such intermediates enhance the microbicidal effect of phagocytes. Several mechanisms enable microorganisms to survive within macrophages. In some instances, intracellular survival appears to depend on the capacity of microorganisms to be endocytized without awakening the host cell oxidative machinery. In addition, the endowment of microorganisms in endogenous enzymatic scavengers of oxygen metabolites may play a role in promoting intracellular survival. These and other mechanisms, such as the property to avoid the harmful effects of lysosomal constituents by inhibiting phagosome-lysosome fusion, or by releasing agents that block the lysosomal enzymatic machinery, may explain why certain microbes are able to survive within activated macrophages.